Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus fulvestrant versus placebo plus fulvestrant in Chinese patients with PIK3CA-mutated HR-positive HER2-negative advanced breast cancer
CTR20200953Phase 2Active
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by Novartis. Started Mar 2021; status: active.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20200953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200953.